A multi-site human clinical trial for a new contact lens care solution with rapid disinfection technology has been completed, according to a press release by Asepticys LLC.
The contact lens solution contains TriFlect technology and provides fast-acting biocidal activity against bacterial, fungal, and viral pathogens.
It was evaluated in clinical trials involving more than 320 patients at 12 sites throughout the United States. The company also announced the submission of a 510k application to the U.S. Food and Drug Administration (FDA).
“TriFlect technology is a breakthrough in disinfection that’s poised to disrupt and become a new benchmark in the $1 billion U.S. contact lens care market,” said Todd Rands, Chief Executive Officer at Asepticys. “The successful human clinical trials represent a major milestone for Asepticys. Once we have final marketing clearance from the FDA, we will quickly move forward with the commercial launch of this disruptive new product.”
Asepticys hopes to launch the product commercially in the coming year.
You can read more here.
Related Content
